Sign in

    Edward Wu

    Research Analyst at Ascendiant Capital

    Edward Wu is an Equity Research Analyst at Ascendiant Capital, specializing in in-depth financial analysis and coverage of emerging healthcare companies, with focused research including firms such as Daxor Corporation. He has a developing public track record, with contributions to sell-side equity research and participation in earnings call analysis for companies under coverage. Wu joined Ascendiant Capital following academic training in finance and accounting, and while his early-stage industry presence limits the availability of performance metrics, he is recognized for his analytical rigor and cross-sector adaptability. He holds applicable securities industry qualifications and is registered with regulatory bodies for equity research activities.

    Edward Wu's questions to DAXOR (DXR) leadership

    Edward Wu's questions to DAXOR (DXR) leadership • Q2 2022

    Question

    Edward Wu asked whether macroeconomic challenges, such as slowing GDP, were affecting Daxor's sales cycle for placing new devices. He also inquired about any supply chain disruptions or inflation-related cost issues the company has faced.

    Answer

    CEO & President Michael Feldschuh responded that in a cost-sensitive economic environment, Daxor's strong value proposition becomes more attractive to hospitals. He explained that the system's ability to shorten patient length-of-stay and serve as a lower-cost alternative to procedures like a right heart cath resonates with economically-focused hospital systems, supported by their partnership with MedAxiom. Regarding operations, he stated that Daxor has avoided significant supply chain problems for components due to its U.S.-based manufacturing but has experienced inflationary pressures related to rising staffing costs.

    Ask Fintool Equity Research AI